TISIDB

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Multi-pass membrane protein. Cell junction. Early endosome. Late endosome. Lysosome. Note=In unstimulated cells, diffuse pattern on plasma membrane. On agonist stimulation, colocalizes with ITCH at the plasma membrane where it becomes ubiquitinated. In the presence of antigen, distributes to the immunological synapse forming at the T-cell-APC contact area, where it localizes at the peripheral and distal supramolecular activation cluster (SMAC).
Domain	PF00001 7 transmembrane receptor (rhodopsin family) PF12109 CXCR4 Chemokine receptor N terminal
Function	Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. ; FUNCTION: (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus (PubMed:9427609, PubMed:10074122, PubMed:10756055). ; FUNCTION: (Microbial infection) Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes.

> Gene Ontology [ TOP ]
Biological Process	GO:0000187 activation of MAPK activity GO:0001666 response to hypoxia GO:0002407 dendritic cell chemotaxis GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0007009 plasma membrane organization GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007272 ensheathment of neurons GO:0008366 axon ensheathment GO:0009615 response to virus GO:0010001 glial cell differentiation GO:0010720 positive regulation of cell development GO:0014013 regulation of gliogenesis GO:0014015 positive regulation of gliogenesis GO:0019058 viral life cycle GO:0019064 fusion of virus membrane with host plasma membrane GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0030260 entry into host cell GO:0030595 leukocyte chemotaxis GO:0032147 activation of protein kinase activity GO:0033674 positive regulation of kinase activity GO:0036293 response to decreased oxygen levels GO:0036336 dendritic cell migration GO:0039663 membrane fusion involved in viral entry into host cell GO:0042063 gliogenesis GO:0042552 myelination GO:0043217 myelin maintenance GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0044409 entry into host GO:0044800 multi-organism membrane fusion GO:0044803 multi-organism membrane organization GO:0045685 regulation of glial cell differentiation GO:0045687 positive regulation of glial cell differentiation GO:0045860 positive regulation of protein kinase activity GO:0046718 viral entry into host cell GO:0048709 oligodendrocyte differentiation GO:0048713 regulation of oligodendrocyte differentiation GO:0048714 positive regulation of oligodendrocyte differentiation GO:0050769 positive regulation of neurogenesis GO:0050900 leukocyte migration GO:0050920 regulation of chemotaxis GO:0051480 regulation of cytosolic calcium ion concentration GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0051962 positive regulation of nervous system development GO:0055074 calcium ion homeostasis GO:0060326 cell chemotaxis GO:0061025 membrane fusion GO:0070098 chemokine-mediated signaling pathway GO:0070482 response to oxygen levels GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis
Molecular Function	GO:0001618 virus receptor activity GO:0001637 G-protein coupled chemoattractant receptor activity GO:0001653 peptide receptor activity GO:0003779 actin binding GO:0004896 cytokine receptor activity GO:0004950 chemokine receptor activity GO:0008528 G-protein coupled peptide receptor activity GO:0015026 coreceptor activity GO:0016494 C-X-C chemokine receptor activity GO:0017022 myosin binding GO:0019955 cytokine binding GO:0031625 ubiquitin protein ligase binding GO:0032027 myosin light chain binding GO:0032182 ubiquitin-like protein binding GO:0043130 ubiquitin binding GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:0005769 early endosome GO:0005770 late endosome GO:0031252 cell leading edge

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04062 Chemokine signaling pathway hsa04144 Endocytosis hsa04360 Axon guidance hsa04670 Leukocyte transendothelial migration hsa04672 Intestinal immune network for IgA production
Reactome	R-HSA-173107: Binding and entry of HIV virion R-HSA-380108: Chemokine receptors bind chemokines R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-1643685: Disease R-HSA-162594: Early Phase of HIV Life Cycle R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-5663205: Infectious disease R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04144 Endocytosis
hsa04360 Axon guidance
hsa04670 Leukocyte transendothelial migration
hsa04672 Intestinal immune network for IgA production

Reactome

R-HSA-173107: Binding and entry of HIV virion
R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1643685: Disease
R-HSA-162594: Early Phase of HIV Life Cycle
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-5663205: Infectious disease
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CXCR4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CXCR4 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25529917	Hepatocellular Carcinoma	Inhibit immunity (T cell function); resistant to immunotherapy	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
25320277	Ovarian Carcinoma	Inhibit immunity (T cell function)	CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
29379494	Chronic Lymphocytic Leukemia	Inhibit immunity (T cell function); immunotherapy target	Here, we show that the CXC chemokine ligand 12 (CXCL12)-CXCR4-STAT3 axis regulates IL-10 production by CLL cells and their ability to suppress T-cell effector function through an IL-10 mediated mechanism. We conclude that the capacity of CLL cells to produce IL-10 is mediated by the CXCL12-CXCR4-STAT3 pathway and likely contributes to immunodeficiency in patients.
18354188	Malignant Skin Neoplasm	Inhibit immunity; immunotherapy target	Mast cells express CXCR4(+) and UV exposure up-regulated the expression of its ligand CXCL12 by lymph node B cells. Treating UV-irradiated mice with a CXCR4 antagonist blocked mast cell migration and abrogated UV-induced immune suppression.
21159639	Lymphoma	Inhibit immunity (T cell function)	CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. In vivo blocking identified the CXCR4/CXCL12 axis as being critical for Treg attraction toward BCL. In contrast to Tregs, effector T cells displayed low levels of CXCR4 and were not affected by the pharmacologic blockade. Most important, blocking CXCR4 not only reduced Treg migration toward tumor tissue but also enhanced antitumor responses after alloHCT.
29036438	Gastric Carcinoma	Inhibit immunity (T cell function)	We generated a xenograft mouse model and used SEW-2871, a S1P1 specific agonist to activate S1P1 signalling. SEW-2871 promoted tumor growth in our mouse model, and induced a higher level of MDSC and a reduced level of CD8+CD69+ T cells within tumor. Additionally, SEW-2871 enhanced expression of several MDSC recruitment-associated chemokines (CXCL12, CXCL5 and CCL2) in tumor cells. These chemokines facilitated MDSC migration by interaction with CCR2, CXCR2 and CXCR4. S1P1 signalling promoted gastric cancer by enhancing chemokine expression in tumor cells and recruiting MDSC to tumor microenvironment, which impaired anti-tumoral function of TILs.
18083706	Cervical Carcinoma; Globlastoma; Breast Carcinoma	Inhibit immunity (T cell function)	Here, we demonstrate that ligand (CXCL12) stimulation of CXCR4, a major chemokine receptor expressed in many malignant cancer cells, induced MHC-I heavy chain down-regulation from the cell surface of the human epithelioid carcinoma HeLa cells, the human U251 and U87 glioblastoma cells, the human MDA-MD 231 breast cancer cells, and the human SK-N-BE (2) neuroblastoma cells. Activation of CXCR4 induced ubiquitination of MHC-I heavy chain, and mutation of the C-terminal two lysine residues (Lys-332, Lys-337) on one of the MHC-I alleles, HLA.B7, blocked CXCR4-evoked ubiquitination and down-regulation of HLA.B7. All together, these findings shed new light on the role of CXCR4 in tumor evasion of immune surveillance via inducing MHC-I down-regulation from the cell surface.
29682201	melanoma	Promote immunity (T cell function); increase the efficacy of immunotherapy	In immunological responder patients, increased protein levels of the chemokine receptor CXCR4 and the Fc-receptor CD32 were observed on cell membranes of CD8+ T and B cells and the monocyte population, respectively, confirming gene expression results.
23871358	Acute Myeloid Leukemia	Inhibit immunity	We envisage future treatment protocols, in which systemic immune activators, such as vaccines, dendritic cell-based therapies, engineered variants of IL-2, or IL-15, are combined with agents that counter immunosuppression mediated by, e.g., the PD/PDL interaction, CTLA-4, CD200, reactive oxygen species, IDO expression, CXCR4, or the KIR/class I interaction, based on characteristics of the prevailing malignant clone.
21521526	Basal-Like Breast Carcinoma	Inhibit immunity (infiltration)	We hypothesised that immune suppression in this subtype may be due to T regulatory cells (Treg) recruitment driven by hypoxia-induced up-regulation of CXCR4 in Treg. Up-regulation of CXCR4 in Treg correlated with the basal-like phenotype (P = 0.029) and tumour hypoxia, as indicated by CA9 expression (P = 0.049). Our data show that in the setting of hypoxia and CXCR4 up-regulation in Treg, CXCL12 expression may have the negative consequence of enhancing Treg recruitment and suppressing the anti-tumour immune response.
22186993	Lymphoid Leukemia; Lymphoma	Inhibit immunity	The chemokine receptor CXCR4, which normally regulates stromal stem cell interactions in the bone marrow, is highly expressed on a variety of malignant hematologic cells, including lymphoma and lymphocytic leukemias. In the present study, we developed pepducins, cell-penetrating lipopeptide antagonists of CXCR4, to interdict CXCL12-CXCR4 transmembrane signaling to intracellular G-proteins. We demonstrate that pepducins targeting the first (i1) or third (i3) intracellular loops of CXCR4 completely abrogate CXCL12-mediated cell migration of lymphocytic leukemias and lymphomas.
21742774	Ovarian Carcinoma	Inhibit immunity	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Similarly, treatment of BR5-1-derived tumors with AMD3100, a selective CXCR4 antagonist, resulted in increased tumor apoptosis and necrosis, reduction in intraperitoneal dissemination, and selective reduction of intratumoral FoxP3(+) regulatory T cells (Treg). Compared with controls, CXCR4 blockade greatly increased T-cell-mediated antitumor immune responses, conferring a significant survival advantage to AMD3100-treated mice.
16990769	leukemia	Promote immunity(infiltration)	Anti-BCP-ALL T cells expressed CD49d and CXCR4 (implicated in the recruitment to bone marrow), and CD62L and CCR7 (involved in the migration to lymphoid organs). In accordance with this profile, T cells significantly migrated in response to the chemokines CXCL12 and CCL19.

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CXCR4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CXCR4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.048	0.927
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.828	0.725
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.531	0.78
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.203	0.693
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.4	0.829
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.055	0.983
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.1	0.847
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.096	0.954
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.283	0.876
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.156	0.936
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.53	0.862
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.257	0.188

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CXCR4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCR4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCR4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCR4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCR4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CXCR4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CXCR4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CXCR4
Name	chemokine (C-X-C motif) receptor 4
Aliases	LESTR; NPY3R; HM89; NPYY3R; D2S201E; fusin; HSY3RR; CD184; chemokine (C-X-C motif), receptor 4 (fusin); FB22 ......
Chromosomal Location	2q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CXCR4 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CXCR4.

ID	Name	Drug Type	Targets	#Targets
DB00452	Framycetin	Small Molecule	CXCR4	1
DB05501	AMD-070	Small Molecule	CCR5, CXCR4	2
DB06809	Plerixafor	Small Molecule	CXCR4	1
DB12698	Ibalizumab	Biotech	CCR5, CD4, CXCR4	3

Browse CXCR4